G. Vatsakis

Enoxaparin for primary thromboprophylaxis in symptomatic outpatients with COVID-19 (OVID): a randomised, open-label, parallel-group, multicentre, phase 3 trial

N. Kucher, G. Colucci, M. Schindewolf, 2022, The Lancet Haematology.